Announcements Trials
Browse Landscape

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Cancer Type

Breast 1

Conditions

Hematologic Neoplasms 4Breast Neoplasms 4Lung Neoplasms 3Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Pancreatic Neoplasms 2Hodgkin Disease 2Gastrointestinal Diseases 2Carcinoma, Non-Small-Cell Lung 2Trastuzumab Cardiotoxicity 1Small Cell Lung Carcinoma 1Sarcopenia 1Radiation Pneumonitis 1Radiation Fibrosis Syndrome 1Pelvic Neoplasms 1Oropharyngeal Neoplasms 1Obesity 1Neoplasms 1Myocardial Fibrosis 1Myelodysplastic Syndromes 1Multiple Myeloma 1Multiple Endocrine Neoplasia Type 1 1Malignant Primary Pelvic Neoplasm 1Lymphoma, Non-Hodgkin 1Leukemia, Myeloid, Acute 1Hereditary Breast and Ovarian Cancer Syndrome 1Heart Diseases 1Heart Defects, Congenital 1Esophageal Neoplasms 1Dyslipidemias 1Colorectal Neoplasms 1

Interventions

Exercise Test 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Observational × Trastuzumab Cardiotoxicity × Exercise Test × Clear all
NCT02615054 2024-04-11

Assessment for Long-Term Cardiovascular Impairment Associated With Trastuzumab Cardiotoxicity in HER2-Positive Breast Cancer Survivors

Memorial Sloan Kettering Cancer Center

Completed
58 enrolled
Breast

Trastuzumab Cardiotoxicity

Data powered by HemOnc (CC BY 4.0) Colophon âš¡